Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.39 |
| ▸ | EDNRA | P25101 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.37 |
| ▸ | PDE4A | P27815 | 3/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30350527 | 1.00 | FFAR4 (0.43) | FFAR4HTR1DHTR2AHTR7HTR2B | |
| SCHEMBL2906852 | 0.81 | PDE4B (0.43) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL1850824 | 0.78 | KDM4E (0.40) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL2908833 | 0.76 | FPR2 (0.41) | — | |
| SCHEMBL441334 | 0.75 | KMT2A (0.39) | — | |
| SCHEMBL23121541 | 0.73 | APP (0.49) | TDP1 | |
| SCHEMBL30350700 | 0.73 | FFAR4 (0.40) | FFAR4PDE4DPDE4APDE4BLRRK2 | |
| SCHEMBL2905574 | 0.73 | PDE4A (0.42) | FFAR4PDE4DPDE4APDE4BLRRK2 | |
| SCHEMBL2910247 | 0.73 | FFAR4 (0.40) | FFAR4PDE4DPDE4APDE4BLRRK2 | |
| SCHEMBL2414177 | 0.72 | APP (0.54) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107567443-B | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2023-04-28 | — | — | CN | disclosed |
| CN-115925679-A | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2023-04-07 | — | — | CN | disclosed |
| EP-3239143-B1 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG CHEMICAL LTD (KR) | 2023-03-22 | — | — | EP | disclosed |
| US-20220135574-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG CHEM, LTD. (KR) | 2022-05-05 | — | — | US | disclosed |
| US-11261186-B2 | Biaryl derivative as GPR120 agonist | LG CHEM. LTD. (KR) | 2022-03-01 | — | — | US | disclosed |
| US-20170349594-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG CHEM, LTD. (KR) | 2017-12-07 | — | — | US | disclosed |
| EP-3239143-A2 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG Chem, Ltd. (KR) | 2017-11-01 | — | — | EP | disclosed |
| EP-1692109-B1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | MEMORY PHARM CORP (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20090118270-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TALAMAS FRANCISCO XAVIER | 2009-05-07 | — | — | US | disclosed |
| US-20070049611-A1 | Phosphodiesterase 4 inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | US | disclosed |
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | MEMORY PHARMACEUTICAL CORPORATION | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049611-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3B, PDE4B | FFAR4 1248/4885HTR1D 641/4885HTR2A 2223/4885 |
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | PDE4A, PDE4B, PDE3B | FFAR4 572/4885HTR1D 344/4885HTR2A 1518/4885 |
| US-20220135574-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | GPR119, GLP1R, GIPR | FFAR4 24/4885HTR1D 1478/4885HTR2A 1214/4885 |
| US-20170349594-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | GPR119, GLP1R, GIPR | FFAR4 24/4885HTR1D 1478/4885HTR2A 1214/4885 |
| US-20090118270-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE4B | FFAR4 1248/4885HTR1D 641/4885HTR2A 2223/4885 |
| US-11261186-B2 | Biaryl derivative as GPR120 agonist | GPR119, GPR88, FFAR1 | FFAR4 18/4885HTR1D 863/4885HTR2A 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.